Aeterna Zentaris Drug Patent Portfolio
Aeterna Zentaris owns 1 orange book drug protected by 2 US patents Given below is the list of Aeterna Zentaris's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8192719 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds | 12 Oct, 2027 | Active |
| US6861409 | Growth hormone secretagogues | 01 Aug, 2022 | Expired |
Latest Legal Activities on Aeterna Zentaris's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aeterna Zentaris.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Nov, 2023 | US8192719 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Nov, 2019 | US8192719 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Jun, 2012 | US8192719 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Jun, 2012 | US8192719 |
| Filing Receipt - Corrected | 30 May, 2012 | US8192719 |
|
Issue Notification Mailed
Critical
| 16 May, 2012 | US8192719 |
| Dispatch to FDC | 08 May, 2012 | US8192719 |
|
Application Is Considered Ready for Issue
Critical
| 02 May, 2012 | US8192719 |
| Filing Receipt - Corrected | 01 May, 2012 | US8192719 |
|
Issue Fee Payment Verified
Critical
| 30 Apr, 2012 | US8192719 |
|
Issue Fee Payment Received
Critical
| 30 Apr, 2012 | US8192719 |
|
Mail Notice of Allowance
Critical
| 29 Mar, 2012 | US8192719 |
|
Case Docketed to Examiner in GAU
Critical
| 26 Mar, 2012 | US8192719 |
|
Notice of Allowance Data Verification Completed
Critical
| 26 Mar, 2012 | US8192719 |
| Date Forwarded to Examiner | 06 Mar, 2012 | US8192719 |
Aeterna Zentaris's Family Patents
Aeterna Zentaris Drug List
Given below is the complete list of Aeterna Zentaris's drugs and the patents protecting them.
1. Macrilen
Macrilen is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8192719 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
12 Oct, 2027
(1 year, 7 months from now)
| Active |
| US6861409 | Growth hormone secretagogues |
01 Aug, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Macrilen's drug page